Adagene (ADAG) Short term Debt (2019 - 2026)
Adagene (ADAG) posted quarterly Short term Debt of $711.4 billion for Q4 2025, down 94.5% year-over-year from $12923.6 billion in Q4 2024, and up 15668621.15% quarter-over-quarter from $4.5 million in Q2 2025.
Adagene (ADAG) Short term Debt (2019 - 2026) Analysis & Trends
Adagene (ADAG) has reported Short term Debt for 7 consecutive years, with $711.4 billion the latest figure, recorded in Q4 2025.
- In Q4 2025, Short term Debt fell 94.5% year-over-year to $711.4 billion; the TTM figure through Dec 2025 stood at $711.4 billion (down 94.5% YoY), while the FY2025 annual figure was $711.4 billion, down 94.5% from the prior year.
- Short term Debt climbed to $711.4 billion in Q4 2025 per ADAG's latest filing, from $4.5 million in the prior quarter.
- Across five years, Short term Debt topped out at $12923.6 billion in Q4 2024 and bottomed at $358958.0 in Q4 2021.
- Historically, Short term Debt has averaged $2459.4 billion across 5 years, with a median of $1031.8 billion in 2022.
- Annual changes were most pronounced in 2022 — Short term Debt soared 794000312.3% — and 2024, when it plunged 100.0%.
- Adagene's Short term Debt stood at $358958.0 in 2021, then jumped by 794000312.3% to $2850.1 billion in 2022, then soared by 46.01% to $4161.5 billion in 2023, then soared by 210.55% to $12923.6 billion in 2024, then sank by 94.5% to $711.4 billion in 2025.
- Business Quant data shows ADAG's Short term Debt at $711.4 billion in Q4 2025, $4.5 million in Q2 2025, and $12923.6 billion in Q4 2024.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) |
|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 128.13 Bn | 120.28 Bn | 2.84 Bn |
| 2 | Regeneron Pharmaceuticals | 112.33 Bn | 104.33 Bn | 3.93 Bn |
| 3 | Argenx Se | 53.24 Bn | 48.05 Bn | 1.41 Bn |
| 4 | Revolution Medicines | 43.64 Bn | 43.64 Bn | - |
| 5 | BeOne Medicines | 39.27 Bn | 34.17 Bn | 1.53 Bn |
| 6 | MindWalk Holdings | 35.32 Bn | 35.31 Bn | 1.82 Bn |
| 7 | Royalty Pharma | 33.72 Bn | 35.84 Bn | - |
| 8 | Alnylam Pharmaceuticals | 30.58 Bn | 27.27 Bn | 992.69 Mn |
| 9 | Insmed | 27.01 Bn | 25.85 Bn | 358.27 Mn |
| 10 | Adagene | 310.54 Mn | 310.54 Mn | - |
Historic Data
Download Data| Date | Value |
|---|---|
| Jun 30, 2026 | 293,647.00 |
| Dec 31, 2025 | 711.36 Bn |
| Jun 30, 2025 | 4.54 Mn |
| Dec 31, 2024 | 12,923.60 Bn |
| Jun 30, 2024 | 11.77 Mn |
| Dec 31, 2023 | 4,161.55 Bn |
| Jun 30, 2023 | 2,594.87 Bn |
| Dec 31, 2022 | 2,850.13 Bn |
| Jun 30, 2022 | 1,352.18 Bn |
| Dec 31, 2021 | 358,958.00 |
| Jun 30, 2021 | 1.82 Mn |
| Dec 31, 2020 | 2.54 Mn |
| Dec 31, 2019 | 1.90 Mn |